The Belgian site of GSK takes big step towards coronavirus vaccine


Several pharmaceutical companies are in the race for a coronavirus vaccine. This is also the case with the British firm GSK, which has a first load of adjuvant ready at its vaccine division in Wavre.

GlaxoSmithKline (GSK), a major player in the field of pharmaceuticals and health products, has announced some happy news. The company is in a strong position in the field of adjuvant technology and can use it in this pandemic. Along with the French firm Sanofi, GSK is working on the development of a coronavirus vaccine. GSK has an initial load of adjuvants, which are a kind of additive, ready to add to the protein for the vaccine candidate. This is necessary to increase the immune response of the vaccinated person and to reduce the amount of vaccine protein needed per dose.

The major advantage is that you can vaccinate more people faster. It is estimated that one billion doses will be available by the end of 2021, according to the Managing Director of GSK Vaccines in Waver.

The European Commission has signed a contract with AstraZeneca, Janssen Pharmaceutica and GSK-Sanofi for the purchase of coronavirus vaccines. This allows Member States to purchase hundreds of millions of doses.

This brings us one step closer to a solution for getting out of this terrible health crisis.